SUTRO BIOPHARMA, INC. Operating Expenses
SUTRO BIOPHARMA, INC. (STRO) reported Operating Expenses of $39.73 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. operating expenses for the quarter ending 2026-06-30 was $39.73M, a 40.79% decline year-over-year.
- SUTRO BIOPHARMA, INC. operating expenses for the quarter ending 2026-03-31 was $44.18M, a 48.58% decline year-over-year.
- SUTRO BIOPHARMA, INC. operating expenses for the quarter ending 2025-12-31 was $49.70M, a 37.93% decline year-over-year.
- SUTRO BIOPHARMA, INC. operating expenses for the quarter ending 2025-09-30 was $58.15M, a 23.92% decline year-over-year.
- SUTRO BIOPHARMA, INC. operating expenses for fiscal 2025 was $260.85M, a 13.19% decline from fiscal 2024.
- SUTRO BIOPHARMA, INC. operating expenses for fiscal 2024 was $300.50M, a 23.66% increase from fiscal 2023.
- SUTRO BIOPHARMA, INC. operating expenses for fiscal 2023 was $243.01M, a 23.53% increase from fiscal 2022.
- SUTRO BIOPHARMA, INC. operating expenses for fiscal 2022 was $196.72M, a 22.64% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $39.73M 10-Q · filed 2026-08-12 | $83.91M 10-Q · filed 2026-08-12 | $133.60M derived: sum of 3 quarters · filed 2026-08-12 | $191.75M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $44.18M 10-Q · filed 2026-05-14 | $93.88M derived: sum of 2 quarters · filed 2026-05-14 | $152.03M derived: sum of 3 quarters · filed 2026-05-14 | $219.12M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $49.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $107.85M derived: sum of 2 quarters · filed 2026-03-23 | $174.94M derived: sum of 3 quarters · filed 2026-08-12 | $260.85M 10-K · filed 2026-03-23 |
| 2025-09-30 | $58.15M 10-Q · filed 2025-11-06 | $125.24M derived: sum of 2 quarters · filed 2026-08-12 | $211.16M 10-Q · filed 2025-11-06 | $291.22M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $67.09M 10-Q · filed 2026-08-12 | $153.00M 10-Q · filed 2026-08-12 | $233.07M derived: sum of 3 quarters · filed 2026-08-12 | $309.51M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $85.91M 10-Q · filed 2026-05-14 | $165.98M derived: sum of 2 quarters · filed 2026-05-14 | $242.42M derived: sum of 3 quarters · filed 2026-05-14 | $316.81M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $80.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $156.51M derived: sum of 2 quarters · filed 2026-03-23 | $230.90M derived: sum of 3 quarters · filed 2026-03-23 | $300.50M 10-K · filed 2026-03-23 |
| 2024-09-30 | $76.44M 10-Q · filed 2025-11-06 | $150.83M derived: sum of 2 quarters · filed 2025-11-06 | $220.43M 10-Q · filed 2025-11-06 | $291.00M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $74.39M 10-Q · filed 2025-08-07 | $143.99M 10-Q · filed 2025-08-07 | $214.56M derived: sum of 3 quarters · filed 2025-08-07 | $275.50M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $69.60M 10-Q · filed 2025-05-08 | $140.17M derived: sum of 2 quarters · filed 2025-05-08 | $201.11M derived: sum of 3 quarters · filed 2025-05-08 | $257.70M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $70.57M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $131.51M derived: sum of 2 quarters · filed 2025-03-13 | $188.10M derived: sum of 3 quarters · filed 2025-03-13 | $243.01M 10-K · filed 2025-03-13 |
| 2023-09-30 | $60.94M 10-Q · filed 2024-11-13 | $117.53M derived: sum of 2 quarters · filed 2024-11-13 | $172.44M 10-Q · filed 2024-11-13 | $230.29M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $56.59M 10-Q · filed 2024-08-13 | $111.50M 10-Q · filed 2024-08-13 | $169.36M derived: sum of 3 quarters · filed 2025-03-13 | $215.71M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $54.91M 10-Q · filed 2024-05-13 | $112.77M derived: sum of 2 quarters · filed 2025-03-13 | $159.12M derived: sum of 3 quarters · filed 2025-03-13 | $206.60M derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $57.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $104.21M derived: sum of 2 quarters · filed 2025-03-13 | $151.69M derived: sum of 3 quarters · filed 2025-03-13 | $196.72M 10-K · filed 2025-03-13 |
| 2022-09-30 | $46.36M 10-Q · filed 2023-11-13 | $93.83M derived: sum of 2 quarters · filed 2023-11-13 | $138.86M 10-Q · filed 2023-11-13 | $184.55M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-06-30 | $47.48M 10-Q · filed 2023-08-10 | $92.50M 10-Q · filed 2023-08-10 | $138.19M derived: sum of 3 quarters · filed 2024-03-25 | $181.38M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-03-31 | $45.03M 10-Q · filed 2023-05-15 | $90.72M derived: sum of 2 quarters · filed 2024-03-25 | $133.91M derived: sum of 3 quarters · filed 2024-03-25 | $171.76M derived: sum of 4 quarters · filed 2024-03-25 |
| 2021-12-31 | $45.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $88.88M derived: sum of 2 quarters · filed 2024-03-25 | $126.73M derived: sum of 3 quarters · filed 2024-03-25 | $160.40M 10-K · filed 2024-03-25 |
| 2021-09-30 | $43.19M 10-Q · filed 2022-11-08 | $81.05M derived: sum of 2 quarters · filed 2022-11-08 | $114.71M 10-Q · filed 2022-11-08 | $147.84M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-06-30 | $37.85M 10-Q · filed 2022-08-08 | $71.52M 10-Q · filed 2022-08-08 | $104.64M derived: sum of 3 quarters · filed 2023-03-30 | $133.08M derived: sum of 4 quarters · filed 2023-03-30 |
| 2021-03-31 | $33.67M 10-Q · filed 2022-05-09 | $66.79M derived: sum of 2 quarters · filed 2023-03-30 | $95.23M derived: sum of 3 quarters · filed 2023-03-30 | $121.12M derived: sum of 4 quarters · filed 2023-03-30 |
| 2020-12-31 | $33.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $61.56M derived: sum of 2 quarters · filed 2023-03-30 | $87.45M derived: sum of 3 quarters · filed 2023-03-30 | $113.78M 10-K · filed 2023-03-30 |
| 2020-09-30 | $28.44M 10-Q · filed 2021-11-10 | $54.33M derived: sum of 2 quarters · filed 2021-11-10 | $80.66M 10-Q · filed 2021-11-10 | $106.75M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $25.89M 10-Q · filed 2021-08-09 | $52.22M 10-Q · filed 2021-08-09 | $78.31M derived: sum of 3 quarters · filed 2022-02-28 | $103.32M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $26.33M 10-Q · filed 2021-05-07 | $52.42M derived: sum of 2 quarters · filed 2022-02-28 | $77.43M derived: sum of 3 quarters · filed 2022-02-28 | $101.64M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $26.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $51.10M derived: sum of 2 quarters · filed 2022-02-28 | $75.31M derived: sum of 3 quarters · filed 2022-02-28 | $98.20M 10-K · filed 2022-02-28 |
| 2019-09-30 | $25.01M 10-Q · filed 2020-11-05 | $49.22M derived: sum of 2 quarters · filed 2020-11-05 | $72.12M 10-Q · filed 2020-11-05 | $94.48M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-06-30 | $24.21M 10-Q · filed 2020-08-06 | $47.10M 10-Q · filed 2020-08-06 | $69.47M derived: sum of 3 quarters · filed 2021-03-18 | $87.46M derived: sum of 4 quarters · filed 2021-03-18 |
| 2019-03-31 | $22.89M 10-Q · filed 2020-05-11 | $45.26M derived: sum of 2 quarters · filed 2021-03-18 | $63.25M derived: sum of 3 quarters · filed 2021-03-18 | $81.04M derived: sum of 4 quarters · filed 2021-03-18 |
| 2018-12-31 | $22.36M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $40.35M derived: sum of 2 quarters · filed 2021-03-18 | $58.15M derived: sum of 3 quarters · filed 2021-03-18 | $75.64M 10-K · filed 2021-03-18 |
| 2018-09-30 | $17.99M 10-Q · filed 2019-11-08 | $35.78M derived: sum of 2 quarters · filed 2019-11-08 | $53.28M 10-Q · filed 2019-11-08 | $72.49M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-06-30 | $17.79M 10-Q · filed 2019-08-14 | $35.29M 10-Q · filed 2019-08-14 | $54.50M derived: sum of 3 quarters · filed 2020-03-16 | $73.06M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-03-31 | $17.50M 10-Q · filed 2019-05-15 | $36.70M derived: sum of 2 quarters · filed 2020-03-16 | $55.27M derived: sum of 3 quarters · filed 2020-03-16 | |
| 2017-12-31 | $19.21M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $37.77M derived: sum of 2 quarters · filed 2020-03-16 | $71.01M 10-K · filed 2020-03-16 | |
| 2017-09-30 | $18.56M 10-Q · filed 2018-11-14 | $51.80M 10-Q · filed 2018-11-14 | ||
| 2016-12-31 | $58.37M 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |